- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01933789
Improving Communication About Serious Illness (ICSI)
Health System Intervention to Improve Communication About End-of-Life Care for Vulnerable Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Four decades of research on end-of-life care indicate that people who are dying often spend their final days with a significant burden of pain and other symptoms and receive care they would not choose. Patient-clinician communication about end-of-life care is an important focus for improving care for three reasons: 1) when it occurs, it is associated with improved quality of life, reduced anxiety, and fewer intensive life-sustaining therapies at the end of life; 2) physicians frequently do not have discussions about end-of-life care with their patients even though most patients desire these discussions; and 3) our preliminary studies suggest that a simple intervention based on each patient's informational needs and preferences can increase the occurrence and quality of patient-clinician communication about end-of-life care. By tailoring patient-clinician discussions to the individual patient, patients will be able to make care decisions that are best for them and clinicians will be able to provide patients with the care patients' desire.
Our long-term goal is to ensure that patients receive the end-of-life care they desire through improved patient-clinician communication. If effective, this health-system intervention will improve: 1) the occurrence and quality of patient-centered communication about end-of-life care for patients with chronic life-limiting illness and their families; 2) the agreement between patients' wishes for care and care received; and 3) the burden of symptoms of anxiety and depression experienced by patients and families.
We propose a randomized trial of a feedback form, called a "Jumpstart" form, provided to patients, family members and clinicians, specifying the individual patient's communication needs and preferences concerning end-of- life care. The trial will be tested with clinicians (n=120) who provide primary or specialty care to eligible patients at clinics of two large healthcare systems. Eligible patients (up to 6 per clinician, goal n=500) will include those with chronic, life-limiting illness. Family members of patients and interdisciplinary team members of primary clinicians may participate. Primary clinicians will be randomized to the intervention or usual care. The intervention's effectiveness will be compared with usual care using validated self-report questionnaires that will be collected longitudinally (baseline/enrollment, within 2 weeks of the target visit, 3 months, 6 months) from patients and families. Analyses include statistical approaches that take into account that there will be more than one patient for each physician and that data are collected at multiple time points.
Outcomes of this study include patient assessments of: 1) frequency and quality of patient/clinician communication; 2) agreement between care patients desire and care patients receive; and 3) symptoms of anxiety and depression.
We will also use qualitative data to accomplish the following goals: 1) to explore subjects' experiences with the study's activities; 2) to understand barriers to participation; and 3) to explore patient and family experiences with the intervention. To obtain these goals, we will contact a total of 30-40 participants, selected from all subject groups, to participate in one-on-one semi-structured interviews during which they will be asked to share their experiences as a study participant and their perspectives on study activities.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Washington
-
Renton, Washington, United States, 98058
- Valley Medical Center
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
Seattle, Washington, United States, 98104
- Harborview Medical Center
-
Seattle, Washington, United States, 98122
- Swedish Medical Center
-
Seattle, Washington, United States, 98133
- Northwest Hospital and Medical Center
-
Seattle, Washington, United States, 98195
- UW Neighborhood Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eligible primary clinicians will include all clinicians who provide ongoing primary or specialty care to eligible patient populations. This will include primary care physicians (family medicine and internal medicine), oncologists, pulmonologists, cardiologists, gastroenterologists, nephrologists, neurologists, hepatologists, and geriatricians. Primary clinicians may also include nurse practitioners and physician assistants playing a "primary role" with eligible patients. A "primary role" denotes any clinician for whom having a discussion about end-of-life care with eligible patients would be indicated
- Eligible interprofessional team members will include nurses, social workers and other clinicians who are part of an enrolled primary clinician's clinic team.
- Eligible patients will be those under the care of a participating clinician who are 18 years of age or older, have had 2 or more visits with the primary clinician in the last 18 months, and meet diagnostic criteria. Diagnostic criteria include: 1) metastatic cancer or inoperable lung cancer; 2) chronic obstructive pulmonary disease with FEV1 values <35% predicted or oxygen dependence or restrictive lung disease with a TLC < 50% predicted; 3) New York Heart Association Class III or IV heart failure; 4) Child's Class C cirrhosis or MELD score of >17; 5) dialysis-dependent renal failure and either diabetes or a serum albumin of < 2.5; or, 6) older than 75 years with at least one life-limiting chronic illness or older than 90 years. Additional criteria include: PAH w. 6MWD <250m, restrictive lung disease (IPF, ILD) w/ TLC <50%, and cystic fibrosis with FEV1 < 30%. Eligible patients will also be English-speaking and have no significant dementia or cognitive impairment that would limit his/her ability to complete questionnaires.
- Eligible family members will be identified by the patient, with the criterion that the patient would want the family member involved in medical decision-making for the patient if he/she was not able. For the purpose of this study, "family member" is not confined to legal next-of-kin or immediate family member. Any family member, friend, or caregiver is eligible who is English-speaking and has no dementia or delirium limiting his/her ability to complete questionnaires.
Exclusion Criteria:
- Reasons for exclusion for all subject groups include: legal or risk management concerns; and physical or mental limitations preventing ability to complete research activities.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Feedback Group
Subjects will complete surveys and assessments and will be given the Communication Feedback Form for Patients with Serious Illness to use prior to and during a target outpatient visit.
|
The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form.
The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address.
Feedback forms are sent to participants prior to the target clinic visit.
The primary clinician's form suggests referral to palliative care if there are "potentially unmet palliative-care communication needs."
All forms include "tips" to help the recipient respond to communication preferences appropriately.
Other Names:
|
No Intervention: Comparison/Usual Care Group
Subjects will only complete surveys and assessments.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Discussion About Goals of Care at Target Visit
Time Frame: 2 weeks after target visit
|
Patient's response to question, "Did you discuss with this doctor the kind of medical care you would want if you were too sick to speak for yourself?"
|
2 weeks after target visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of Discussion About Goals of Care at Target Visit
Time Frame: Target visit
|
Electronic Health Record (EHR) documentation of discussion about advance care planning, prognosis, treatment preference, hospice, palliative care, or Physician Orders for Life-Sustaining Treatment (POLST) at target visit
|
Target visit
|
Occurrence of Discussion About Goals of Care at Target Visit Among Patients Who Did Not Object to Future Discussion at Baseline
Time Frame: 2 weeks after target visit
|
Patient's response to question, "Did you discuss with this doctor the kind of medical care you would want if you were too sick to speak for yourself?"
|
2 weeks after target visit
|
Occurrence of Discussion About Goals of Care at Target Visit Among Patients Who Did Not Object to Future Discussion at Baseline
Time Frame: Target visit
|
Electronic Health Record (EHR) documentation of discussion about advance care planning, prognosis, treatment preference, hospice, palliative care, or Physician Orders for Life-Sustaining Treatment (POLST) at target visit
|
Target visit
|
Goal-Concordant Care
Time Frame: 3 months after target visit
|
Binary variable indicating whether patient's reported focus of current treatment was concordant with treatment preference
|
3 months after target visit
|
Goal-Concordant Care Among Patients With Stable Treatment Preference
Time Frame: 3 months after target visit
|
Binary variable indicating whether patient's reported focus of current treatment was concordant with treatment preference
|
3 months after target visit
|
Quality of Communication (QOC): Four-Indicator Latent Construct
Time Frame: 2 weeks from target visit
|
Quality of Communication: patient ratings of clinician on seven aspects of end-of-life communication, each aspect having a pseudo-continuous response range of 0 ('clinician didn't do this') to 11 ('the very best I could imagine'). Measured with QOC items 1, 2, 5, & 6 (measurement invariance imposed between groups and over time). Outcome is a latent variable, which is not observable, nor is it a composite score that can be mathematically computed (e.g., as a sum or average) from its measured indicators. Instead, it is an abstract construct that is inferred through a mathematical model; it represents a concept and is, therefore, a hypothetical variable. Theoretical range: unknown; the latent variable is a hypothetical - not an actual - variable Actual range: inapplicable; cannot be determined; this is an indirectly-measured latent variable; Higher value indicates better outcome (i.e., higher quality communication) Unit of measurement: scores on a scale |
2 weeks from target visit
|
Quality of Communication (QOC): Individual QOC Items
Time Frame: 2 weeks from target visit
|
Quality of Communication: patient ratings of clinician on seven aspects of end-of-life communication, each aspect having a pseudo-continuous response range of 0 ('clinician didn't do this') to 11 ('the very best I could imagine'). Individual QOC Items. Theoretical range: 0-11 Actual range: 0-11 Higher value indicates better outcome (i.e., higher quality communication) Unit of measurement: units on a scale |
2 weeks from target visit
|
Patient Health Questionnaire (PHQ-8): Two-Indicator Latent Construct
Time Frame: 3 months after target visit
|
Patient Health Questionnaire: A self-report measure of depressive symptoms. Eight symptoms, each with ordinal response options, each option associated with a text description ranging from 'Not at all' to 'Nearly every day'. Two-Indicator Latent Construct: Measured with PHQ items 1 & 2 (measurement invariance imposed between groups and over time). Outcome is a latent variable, which is not observable, nor is it a composite score that can be mathematically computed (e.g., as a sum or average) from its measured indicators. Instead, it is an abstract construct that is inferred through a mathematical model; it represents a concept and is, therefore, a hypothetical variable. Theoretical range: unknown; the latent variable is a hypothetical - not an actual - variable Actual range: inapplicable; cannot be determined; this is an indirectly-measured latent variable Higher value indicates worse outcome (i.e., higher level of depressive symptoms) Unit of measurement: scores on a scale |
3 months after target visit
|
Patient Health Questionnaire (PHQ-8): Eight-Item Scale
Time Frame: 3 months after target visit
|
Patient Health Questionnaire: A self-report measure of depressive symptoms. Eight symptoms, each with ordinal response options, each option associated with a text description ranging from 'Not at all' to 'Nearly every day'. Eight-Item Scale: Sum of responses for the eight symptoms (weighted by 8/7 if only 7 items answered). Theoretical range: 0-24 Actual range: 0-24 Higher value indicates worse outcome (i.e., higher level of depressive symptoms) Unit of measurement: scores on a scale |
3 months after target visit
|
Patient Health Questionnaire (PHQ-8): Two-Indicator Latent Construct
Time Frame: 6 months after target visit
|
Patient Health Questionnaire: A self-report measure of depressive symptoms. Eight symptoms, each with ordinal response options, each option associated with a text description ranging from 'Not at all' to 'Nearly every day'. Two-Indicator Latent Construct: Measured with PHQ items 1 & 2 (measurement invariance imposed between groups and over time). Outcome is a latent variable, which is not observable, nor is it a composite score that can be mathematically computed (e.g., as a sum or average) from its measured indicators. Instead, it is an abstract construct that is inferred through a mathematical model; it represents a concept and is, therefore, a hypothetical variable. Theoretical range: unknown; the latent variable is a hypothetical - not an actual - variable Actual range: inapplicable; cannot be determined; this is an indirectly-measured latent variable Higher value indicates worse outcome (i.e., higher level of depressive symptoms) Unit of measurement: scores on a scale |
6 months after target visit
|
Patient Health Questionnaire (PHQ-8): Eight-Item Scale
Time Frame: 6 months after target visit
|
Patient Health Questionnaire: A self-report measure of depressive symptoms. Eight symptoms, each with ordinal response options, each option associated with a text description ranging from 'Not at all' to 'Nearly every day'. Eight-Item Scale: Sum of responses for the eight symptoms (weighted by 8/7 if only 7 items answered). Theoretical range: 0-24 Actual range: 0-24 Higher value indicates worse outcome (i.e., higher level of depressive symptoms) Unit of measurement: scores on a scale |
6 months after target visit
|
Generalized Anxiety Disorder (GAD-7): Two-Indicator Latent Construct
Time Frame: 3 months after target visit
|
Generalized Anxiety Disorder: A self-report measure of anxiety symptoms. Seven symptoms, each with ordinal response options, each option associated with a text description ranging from 'Not at all' to 'Nearly every day'. Two-Indicator Latent Construct: Measured with GAD items 1 & 2 (measurement invariance imposed between groups and over time). Outcome is a latent variable, which is not observable, nor is it a composite score that can be mathematically computed (e.g., as a sum or average) from its measured indicators. Instead, it is an abstract construct that is inferred through a mathematical model; it represents a concept and is, therefore, a hypothetical variable. Theoretical range: unknown; the latent variable is a hypothetical - not an actual - variable Actual range: inapplicable; cannot be determined; this is an indirectly-measured latent variable Higher value indicates worse outcome (i.e., higher level of anxiety symptoms) Unit of measurement: scores on a scale |
3 months after target visit
|
Generalized Anxiety Disorder (GAD-7): Seven-Item Scale
Time Frame: 3 months after target visit
|
Generalized Anxiety Disorder: A self-report measure of anxiety symptoms. Seven symptoms, each with ordinal response options, each option associated with a text description ranging from 'Not at all' to 'Nearly every day'. Seven-Item Scale: Sum of responses for the seven symptoms (weighted by 7/6 if only 6 items answered). (Strong floor effect.) Theoretical range: 0-21 Actual range: 0-21 Higher value indicates worse outcome (i.e., higher level of anxiety symptoms) Unit of measurement: scores on a scale |
3 months after target visit
|
Generalized Anxiety Disorder (GAD-7): Two-Indicator Latent Construct
Time Frame: 6 months after target visit
|
Generalized Anxiety Disorder: A self-report measure of anxiety symptoms. Seven symptoms, each with ordinal response options, each option associated with a text description ranging from 'Not at all' to 'Nearly every day'. Two-Indicator Latent Construct: Measured with GAD items 1 & 2 (measurement invariance imposed between groups and over time). Outcome is a latent variable, which is not observable, nor is it a composite score that can be mathematically computed (e.g., as a sum or average) from its measured indicators. Instead, it is an abstract construct that is inferred through a mathematical model; it represents a concept and is, therefore, a hypothetical variable. Theoretical range: unknown; the latent variable is a hypothetical - not an actual - variable Actual range: inapplicable; cannot be determined; this is an indirectly-measured latent variable Higher value indicates worse outcome (i.e., higher level of anxiety symptoms) Unit of measurement: scores on a scale |
6 months after target visit
|
Generalized Anxiety Disorder (GAD-7): Seven-Item Scale
Time Frame: 6 months after target visit
|
Generalized Anxiety Disorder: A self-report measure of anxiety symptoms. Seven symptoms, each with ordinal response options, each option associated with a text description ranging from 'Not at all' to 'Nearly every day'. Seven-Item Scale: Sum of responses for the seven symptoms (weighted by 7/6 if only 6 items answered). (Strong floor effect.) Theoretical range: 0-21 Actual range: 0-21 Higher value indicates worse outcome (i.e., higher level of anxiety symptoms) Unit of measurement: scores on a scale |
6 months after target visit
|
Avoidance of Life-Sustaining Therapies, All Patients
Time Frame: 6-month period following the target visit
|
Review of EHR documentation to assess use of three indicators of life-sustaining therapies (LST): admission to an ICU, receipt of CPR, and receipt of mechanical ventilation
|
6-month period following the target visit
|
Avoidance of Life-Sustaining Therapies, Patients With Comfort Care Preference
Time Frame: 6-month period following the target visit
|
Review of EHR documentation to assess use of three indicators of life-sustaining therapies (LST): admission to an ICU, receipt of CPR, and receipt of mechanical ventilation for patients preferring "comfort" (quality of life over extending life) at the end-of-life
|
6-month period following the target visit
|
Palliative Care Consultation, Inpatient Stay - All Patients
Time Frame: 3-month period following the target visit
|
EHR documentation of palliative care consultation during an inpatient stay for all patients with target visit and chart abstraction.
|
3-month period following the target visit
|
Palliative Care Consultation, Inpatient Stay - Patients Most Likely to Benefit
Time Frame: 3-month period following the target visit
|
EHR documentation of palliative care consultation during an inpatient stay for patients who reported preference for "comfort care" (quality of life over extending life) and wanted a discussion.
|
3-month period following the target visit
|
Palliative Care Consultation, Inpatient Stay - All Patients
Time Frame: 6-month period following the target visit
|
EHR documentation of palliative care consultation during an inpatient stay for all patients with target visit and chart abstraction.
|
6-month period following the target visit
|
Palliative Care Consultation, Inpatient Stay - Patients Most Likely to Benefit
Time Frame: 6-month period following the target visit
|
EHR documentation of palliative care consultation during an inpatient stay for patients who reported preference for "comfort care" (quality of life over extending life) and wanted a discussion.
|
6-month period following the target visit
|
Palliative Care Referral, Outpatient Visit - All Patients
Time Frame: 3-month period following the target visit
|
EHR documentation of referral to palliative care services, or discussion about a referral, during an outpatient visit.
|
3-month period following the target visit
|
Palliative Care Referral, Outpatient Visit - Patients Most Likely to Benefit
Time Frame: 3-month period following the target visit
|
EHR documentation of referral to palliative care services, or discussion about a referral, during an outpatient visit for patients who reported preference for "comfort care" (quality of life over extending life) and wanted a discussion.
|
3-month period following the target visit
|
Palliative Care Referral, Outpatient Visit - All Patients
Time Frame: 6-month period following the target visit
|
EHR documentation of referral to palliative care services, or discussion about a referral, during an outpatient visit.
|
6-month period following the target visit
|
Palliative Care Referral, Outpatient Visit - Patients Most Likely to Benefit
Time Frame: 6-month period following the target visit
|
EHR documentation of referral to palliative care services, or discussion about a referral, during an outpatient visit for patients who reported preference for "comfort care" (quality of life over extending life) and wanted a discussion.
|
6-month period following the target visit
|
Palliative Care Consultation and/or Referral - All Patients
Time Frame: 3-month period following the target visit
|
EHR documentation of palliative care referral during an outpatient visit and/or palliative care consultation during an inpatient stay.
|
3-month period following the target visit
|
Palliative Care Consultation and/or Referral - Patients Most Likely to Benefit
Time Frame: 3-month period following the target visit
|
EHR documentation of palliative care referral during an outpatient visit and/or palliative care consultation during an inpatient stay for patients who reported preference for "comfort care" (quality of life over extending life) and wanted a discussion.
|
3-month period following the target visit
|
Palliative Care Consultation and/or Referral - All Patients
Time Frame: 6-month period following the target visit
|
EHR documentation of palliative care referral during an outpatient visit and/or palliative care consultation during an inpatient stay.
|
6-month period following the target visit
|
Palliative Care Consultation and/or Referral - Patients Most Likely to Benefit
Time Frame: 6-month period following the target visit
|
EHR documentation of palliative care referral during an outpatient visit and/or palliative care consultation during an inpatient stay for patients who reported preference for "comfort care" (quality of life over extending life) and wanted a discussion.
|
6-month period following the target visit
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Group Differences - Treatment Preference (Adjustment Variable for Outcome Measuring Goal-concordant Care)
Time Frame: 3 months after target visit
|
Binary variable indicating whether patient's current preference was for life-extension or comfort care
|
3 months after target visit
|
Group Differences - Stable Treatment Preference (Filter for Subgroup Analysis of Goal-concordant Care)
Time Frame: 3 months after target visit
|
Binary variable indicating whether patient's treatment preference was stable between target visit (or baseline, if no 2-week questionnaire was returned) and 3 months.
|
3 months after target visit
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Au DH, Udris EM, Engelberg RA, Diehr PH, Bryson CL, Reinke LF, Curtis JR. A randomized trial to improve communication about end-of-life care among patients with COPD. Chest. 2012 Mar;141(3):726-735. doi: 10.1378/chest.11-0362. Epub 2011 Sep 22.
- Knauft E, Nielsen EL, Engelberg RA, Patrick DL, Curtis JR. Barriers and facilitators to end-of-life care communication for patients with COPD. Chest. 2005 Jun;127(6):2188-96. doi: 10.1378/chest.127.6.2188.
- Curtis JR, Patrick DL. Barriers to communication about end-of-life care in AIDS patients. J Gen Intern Med. 1997 Dec;12(12):736-41. doi: 10.1046/j.1525-1497.1997.07158.x.
- Curtis JR, Engelberg RA, Nielsen EL, Au DH, Patrick DL. Patient-physician communication about end-of-life care for patients with severe COPD. Eur Respir J. 2004 Aug;24(2):200-5. doi: 10.1183/09031936.04.00010104.
- Engelberg R, Downey L, Curtis JR. Psychometric characteristics of a quality of communication questionnaire assessing communication about end-of-life care. J Palliat Med. 2006 Oct;9(5):1086-98. doi: 10.1089/jpm.2006.9.1086.
- Curtis JR, Wenrich MD, Carline JD, Shannon SE, Ambrozy DM, Ramsey PG. Patients' perspectives on physician skill in end-of-life care: differences between patients with COPD, cancer, and AIDS. Chest. 2002 Jul;122(1):356-62. doi: 10.1378/chest.122.1.356.
- Coats H, Downey L, Sharma RK, Curtis JR, Engelberg RA. Quality of Communication and Trust in Patients With Serious Illness: An Exploratory Study of the Relationships of Race/Ethnicity, Socioeconomic Status, and Religiosity. J Pain Symptom Manage. 2018 Oct;56(4):530-540.e6. doi: 10.1016/j.jpainsymman.2018.07.005. Epub 2018 Jul 17.
- Curtis JR, Downey L, Back AL, Nielsen EL, Paul S, Lahdya AZ, Treece PD, Armstrong P, Peck R, Engelberg RA. Effect of a Patient and Clinician Communication-Priming Intervention on Patient-Reported Goals-of-Care Discussions Between Patients With Serious Illness and Clinicians: A Randomized Clinical Trial. JAMA Intern Med. 2018 Jul 1;178(7):930-940. doi: 10.1001/jamainternmed.2018.2317.
- Fakhri S, Engelberg RA, Downey L, Nielsen EL, Paul S, Lahdya AZ, Treece PD, Curtis JR. Factors Affecting Patients' Preferences for and Actual Discussions About End-of-Life Care. J Pain Symptom Manage. 2016 Sep;52(3):386-94. doi: 10.1016/j.jpainsymman.2016.03.012. Epub 2016 Jun 3.
Helpful Links
- Click here for more information about this study. PCORI Project Summary: Health System Intervention to Improve Communication about End-of-Life Care for Vulnerable Patients
- The End-of-Life Care Research Program at the UW School of Medicine
- The Palliative Care Center of Excellence at the University of Washington
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Liver Failure
- Hepatic Insufficiency
- Pathologic Processes
- Respiratory Tract Diseases
- Lung Diseases
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Disease Attributes
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Neoplastic Processes
- Lung Diseases, Obstructive
- Renal Insufficiency, Chronic
- Liver Diseases
- End Stage Liver Disease
- Neoplasms
- Pulmonary Disease, Chronic Obstructive
- Lung Neoplasms
- Neoplasm Metastasis
- Kidney Failure, Chronic
- Renal Insufficiency
- Chronic Disease
- Critical Illness
Other Study ID Numbers
- 44023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End Stage Liver Disease
-
University of ZurichUniversity Ghent; University Hospital of Sao Paulo, BrazilCompleted
-
Vanderbilt University Medical CenterEnrolling by invitationEnd Stage Liver DIseaseUnited States
-
Virginia Commonwealth UniversityCompletedEnd Stage Liver DIseaseUnited States
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonCompletedEnd-stage Liver DiseaseUnited Kingdom
-
Proteonomix, Inc.University of Medicine and Dentistry of New Jersey; NumodaUnknownEnd Stage Liver DIseaseUnited States
-
RenJi HospitalNot yet recruitingEnd Stage Liver DIsease
-
Mayo ClinicRecruiting
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Huashan HospitalRecruiting
-
Beijing Chao Yang HospitalUnknownLiver Transplantation | End Stage Liver DIseaseChina
Clinical Trials on Communication Feedback Form for Patients with Serious Illness
-
Universitätsklinikum Hamburg-EppendorfRecruitingCarcinoma | Palliative Care | Malignant NeoplasmGermany
-
University of California, San DiegoRecruitingObesity | Diabetes | Schizophrenia | Serious Mental Illness | Lifestyle Risk ReductionUnited States
-
Vanderbilt-Ingram Cancer CenterEntrinsic Bioscience Inc.TerminatedNeuroendocrine Tumor | Carcinoid SyndromeUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingMetastatic Solid Tumor Cancers | Locally Advanced Solid Tumor CancersUnited States
-
Washington University School of MedicineTerminated
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompleted
-
Umm Al-Qura UniversityRecruitingPHYSICAL THERAPY TECHNIQUESSaudi Arabia
-
Geisinger ClinicNational Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationFamilial HypercholesterolemiaUnited States